Allergic adverse events following 2015 seasonal influenza vaccine, Victoria, Australia

Hazel Joanne Clothier, N. W. Crawford, M. A. Russell, J. P. Buttery

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Australia was alerted to a possible increase in allergyrelated adverse events following immunisation (AEFI) with 2015 seasonal trivalent influenza vaccines (TIV) by the Victorian state vaccine safety service, SAEFVIC. We describe SAEFVIC’s initial investigation and upon conclusion of the 2015 influenza vaccination programme, to define the signal event and implications for vaccine programmes. Allergy-related AEFI were defined as anaphylaxis, angioedema, urticaria or generalised allergic reaction. Investigations compared 2015 TIV AEFI reports to previous years as proportions and reporting risk (RR) per 100,000, stratified by influenza vaccine brand. The initial investigation showed an increased proportion of allergy-related AEFI compared with 2014 (25% vs 12%), predominantly in adults, with insufficient clinical severity to alter the programme risk-benefit. While overall TIV AEFI RR in 2015 was similar to previous years (RR: 1.07, 95% confidence interval (CI): 0.88−1.29), we identified a near-doubling RR for allergy-related AEFI in 2015 (RR: 1.78, 95% CI: 1.14− 2.80) from 2011 to 2014 with no difference by vaccine brand or severity increase identified. This increase in generalised allergy-related AEFI, across all used vaccine brands, supports evidence of variable reactogenicity arising from influenza vaccine strain variations. This investigation underlines the importance of effective seasonal influenza vaccine pharmacovigilance.

Original languageEnglish
Article number30535
Pages (from-to)1-7
Number of pages7
JournalEurosurveillance
Volume22
Issue number20
DOIs
Publication statusPublished - 18 May 2017

Cite this

Clothier, Hazel Joanne ; Crawford, N. W. ; Russell, M. A. ; Buttery, J. P. / Allergic adverse events following 2015 seasonal influenza vaccine, Victoria, Australia. In: Eurosurveillance. 2017 ; Vol. 22, No. 20. pp. 1-7.
@article{999bc7b034ea4c4481e8502659d95ca5,
title = "Allergic adverse events following 2015 seasonal influenza vaccine, Victoria, Australia",
abstract = "Australia was alerted to a possible increase in allergyrelated adverse events following immunisation (AEFI) with 2015 seasonal trivalent influenza vaccines (TIV) by the Victorian state vaccine safety service, SAEFVIC. We describe SAEFVIC’s initial investigation and upon conclusion of the 2015 influenza vaccination programme, to define the signal event and implications for vaccine programmes. Allergy-related AEFI were defined as anaphylaxis, angioedema, urticaria or generalised allergic reaction. Investigations compared 2015 TIV AEFI reports to previous years as proportions and reporting risk (RR) per 100,000, stratified by influenza vaccine brand. The initial investigation showed an increased proportion of allergy-related AEFI compared with 2014 (25{\%} vs 12{\%}), predominantly in adults, with insufficient clinical severity to alter the programme risk-benefit. While overall TIV AEFI RR in 2015 was similar to previous years (RR: 1.07, 95{\%} confidence interval (CI): 0.88−1.29), we identified a near-doubling RR for allergy-related AEFI in 2015 (RR: 1.78, 95{\%} CI: 1.14− 2.80) from 2011 to 2014 with no difference by vaccine brand or severity increase identified. This increase in generalised allergy-related AEFI, across all used vaccine brands, supports evidence of variable reactogenicity arising from influenza vaccine strain variations. This investigation underlines the importance of effective seasonal influenza vaccine pharmacovigilance.",
author = "Clothier, {Hazel Joanne} and Crawford, {N. W.} and Russell, {M. A.} and Buttery, {J. P.}",
year = "2017",
month = "5",
day = "18",
doi = "10.2807/1560-7917.ES.2017.22.20.30535",
language = "English",
volume = "22",
pages = "1--7",
journal = "Eurosurveillance",
issn = "1025-496X",
publisher = "European Centre for Disease Prevention and Control",
number = "20",

}

Allergic adverse events following 2015 seasonal influenza vaccine, Victoria, Australia. / Clothier, Hazel Joanne; Crawford, N. W.; Russell, M. A.; Buttery, J. P.

In: Eurosurveillance, Vol. 22, No. 20, 30535, 18.05.2017, p. 1-7.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Allergic adverse events following 2015 seasonal influenza vaccine, Victoria, Australia

AU - Clothier, Hazel Joanne

AU - Crawford, N. W.

AU - Russell, M. A.

AU - Buttery, J. P.

PY - 2017/5/18

Y1 - 2017/5/18

N2 - Australia was alerted to a possible increase in allergyrelated adverse events following immunisation (AEFI) with 2015 seasonal trivalent influenza vaccines (TIV) by the Victorian state vaccine safety service, SAEFVIC. We describe SAEFVIC’s initial investigation and upon conclusion of the 2015 influenza vaccination programme, to define the signal event and implications for vaccine programmes. Allergy-related AEFI were defined as anaphylaxis, angioedema, urticaria or generalised allergic reaction. Investigations compared 2015 TIV AEFI reports to previous years as proportions and reporting risk (RR) per 100,000, stratified by influenza vaccine brand. The initial investigation showed an increased proportion of allergy-related AEFI compared with 2014 (25% vs 12%), predominantly in adults, with insufficient clinical severity to alter the programme risk-benefit. While overall TIV AEFI RR in 2015 was similar to previous years (RR: 1.07, 95% confidence interval (CI): 0.88−1.29), we identified a near-doubling RR for allergy-related AEFI in 2015 (RR: 1.78, 95% CI: 1.14− 2.80) from 2011 to 2014 with no difference by vaccine brand or severity increase identified. This increase in generalised allergy-related AEFI, across all used vaccine brands, supports evidence of variable reactogenicity arising from influenza vaccine strain variations. This investigation underlines the importance of effective seasonal influenza vaccine pharmacovigilance.

AB - Australia was alerted to a possible increase in allergyrelated adverse events following immunisation (AEFI) with 2015 seasonal trivalent influenza vaccines (TIV) by the Victorian state vaccine safety service, SAEFVIC. We describe SAEFVIC’s initial investigation and upon conclusion of the 2015 influenza vaccination programme, to define the signal event and implications for vaccine programmes. Allergy-related AEFI were defined as anaphylaxis, angioedema, urticaria or generalised allergic reaction. Investigations compared 2015 TIV AEFI reports to previous years as proportions and reporting risk (RR) per 100,000, stratified by influenza vaccine brand. The initial investigation showed an increased proportion of allergy-related AEFI compared with 2014 (25% vs 12%), predominantly in adults, with insufficient clinical severity to alter the programme risk-benefit. While overall TIV AEFI RR in 2015 was similar to previous years (RR: 1.07, 95% confidence interval (CI): 0.88−1.29), we identified a near-doubling RR for allergy-related AEFI in 2015 (RR: 1.78, 95% CI: 1.14− 2.80) from 2011 to 2014 with no difference by vaccine brand or severity increase identified. This increase in generalised allergy-related AEFI, across all used vaccine brands, supports evidence of variable reactogenicity arising from influenza vaccine strain variations. This investigation underlines the importance of effective seasonal influenza vaccine pharmacovigilance.

UR - http://www.scopus.com/inward/record.url?scp=85019860031&partnerID=8YFLogxK

U2 - 10.2807/1560-7917.ES.2017.22.20.30535

DO - 10.2807/1560-7917.ES.2017.22.20.30535

M3 - Article

VL - 22

SP - 1

EP - 7

JO - Eurosurveillance

JF - Eurosurveillance

SN - 1025-496X

IS - 20

M1 - 30535

ER -